Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...
Wedbush assumed coverage of Passage Bio (PASG) with an Outperform rating and price target of $4, up from $3. Market sentiment ...